Chinese Journal of Physiology

ORIGINAL ARTICLE
Year
: 2019  |  Volume : 62  |  Issue : 4  |  Page : 157--165

Aloperine suppresses human pulmonary vascular smooth muscle cell proliferation via inhibiting inflammatory response


Zhi Chang1, Peng Zhang2, Min Zhang1, Feng Jun1, Zhiqiang Hu2, Jiamei Yang1, Yuhua Wu2, Ru Zhou3 
1 Department of Pharmacology, College of Pharmacy, Ningxia Medical University, Yinchuan 750004, PR China
2 General Hospital of Ningxia Medical University, Yinchuan 750004, PR China
3 Department of Pharmacology, College of Pharmacy; Key Laboratory of Hui Ethnic Medicine Modernization, Ministry of Education; Ningxia Hui Medicine Modern Engineering Research Center and Collaborative Innovation Center, Ningxia Medical University, Yinchuan 750004, PR China

Correspondence Address:
Prof. Ru Zhou
Department of Pharmacology, Ningxia Medical University, 1160 Shengli Street, Yinchuan 750004
PR China
Prof. Yuhua Wu
General Hospital of Ningxia Medical University, 804 Shengli Street, Yinchuan 750004
PR China

Abnormal pulmonary arterial vascular smooth muscle cells (PASMCs) proliferation is critical pathological feature of pulmonary vascular remodeling that acts as driving force in the initiation and development of pulmonary arterial hypertension (PAH), ultimately leading to pulmonary hypertension. Aloperine is a main active alkaloid extracted from the traditional Chinese herbal Sophora alopecuroides and possesses outstanding antioxidation and anti-inflammatory effects. Our group found Aloperine has protective effects on monocroline-induced pulmonary hypertension in rats by inhibiting oxidative stress in previous researches. However, the anti-inflammation effects of Aloperine on PAH remain unclear. Therefore, to further explore whether the beneficial role of Aloperine on PAH was connected with its anti-inflammatory effects, we performed experiments in vitro. Aloperine significantly inhibited the proliferation and DNA synthesis of human pulmonary artery smooth muscle cells (HPASMCs) induced by platelet-derived growth factor-BB, blocked progression through G0/G1to S phase of the cell cycle and promoted total ratio of apoptosis. In summary, these results suggested that Aloperine negatively regulated nuclear factor-κB signaling pathway activity to exert protective effects on PAH and suppressed HPASMCs proliferation therefore has a potential value in the treatment of pulmonary hypertension by negatively modulating pulmonary vascular remodeling.


How to cite this article:
Chang Z, Zhang P, Zhang M, Jun F, Hu Z, Yang J, Wu Y, Zhou R. Aloperine suppresses human pulmonary vascular smooth muscle cell proliferation via inhibiting inflammatory response.Chin J Physiol 2019;62:157-165


How to cite this URL:
Chang Z, Zhang P, Zhang M, Jun F, Hu Z, Yang J, Wu Y, Zhou R. Aloperine suppresses human pulmonary vascular smooth muscle cell proliferation via inhibiting inflammatory response. Chin J Physiol [serial online] 2019 [cited 2019 Sep 15 ];62:157-165
Available from: http://www.cjphysiology.org/article.asp?issn=0304-4920;year=2019;volume=62;issue=4;spage=157;epage=165;aulast=Chang;type=0